For example, STAT3 is frequently activated and plays oncogenic roles in non-small cell lung adenocarcinomas with the context of EGFR driver mutations, whereas low STAT3 level correlate with increased malignant progression and poor prognosis in lung cancer patients with KRAS mutations. This evidence concerns the gene KRAS and lung carcinoma.